Coeptis collaborates with University of Pittsburgh on SNAP-CAR T cells targeting HER2-positive cancers

Feb. 1, 2023

Coeptis Therapeutics Holdings Inc. has entered into a sponsored research agreement with the University of Pittsburgh to advance preclinical development of SNAP-CAR T cells targeting HER2, and to explore opportunities to expand the applicability of SNAP-CAR in oncology.

BioWorld Science Collaboration CAR T Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for March 23, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 23, 2022.

Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

BioWorld

Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...

AI drug discovery startup Protai raises $12M in seed funding

BioWorld

Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...

Flagship puts $50M toward targeted tissue-homing tech startup

BioWorld

In an ideal world, when a patient takes a medicine, it acts only at the specific site of disease in the human body whilst sparing healthy tissues. But it almost...

Upgrade your daily dose of biopharma and medtech news

Coeptis collaborates with University of Pittsburgh on SNAP-CAR T cells targeting HER2-positive cancers